Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC.FENC · Entity 5601 | Director | September 15, 2026 | September 16, 2026 |
| SOLIGENIX, INC.SNGX · Entity 8067 | Director | June 08, 2017 | June 12, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FENNEC PHARMACEUTICALS INC.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 15,545 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 15,545 · Balance 15,545 F1: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on June 16, 2026. |
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-15 · Sale · Disposed 15,545 · Balance 0 F2: Shares sold pursuant to a 10b5-1 plan adopted on June 16, 2026. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.11 · Expires 2026-12-30 | Direct | 220,000 |
Reported balance
After 2026-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Disposed 15,545 · Balance 220,000 F3: Represents options exercised pursuant to a 10b5-1 plan adopted on June 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on June 16, 2026.
F2: Shares sold pursuant to a 10b5-1 plan adopted on June 16, 2026.
F3: Represents options exercised pursuant to a 10b5-1 plan adopted on June 16, 2026.
SOLIGENIX, INC.
Report date June 08, 2017 · Filed June 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.29 · Expires 2027-06-07 | Direct | 13,100 |
Reported balance
After 2017-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 13,100 · Balance 13,100 F1: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionStock Option · Derivative | 15,545 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001589776-26-000004 · form4-09162026_040901.xml · derivative · entry 3 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,000 Underlying: Common shares · 15,545 shares Expires 2026-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Represents options exercised pursuant to a 10b5-1 plan adopted on June 16, 2026. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | SaleCommon Shares | 15,545 | $10.29 | $159,958.05 |
DisclosureSEC source: 0001589776-26-000004 · form4-09162026_040901.xml · nonDerivative · entry 2 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F2 · security: Shares sold pursuant to a 10b5-1 plan adopted on June 16, 2026. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:05 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | Exercise / conversionCommon Shares | 15,545 | $2.11 | $32,799.95 |
DisclosureSEC source: 0001589776-26-000004 · form4-09162026_040901.xml · nonDerivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on June 16, 2026. Read SEC document |
| June 10, 2026 Filed Jun 10, 2026 21:50 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $8.70 Strike: $8.70 | $174,000.00 |
DisclosureSEC source: 0001589776-26-000002 · form4-06102026_090632.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,545 Underlying: Common shares · 20,000 shares Expires 2036-06-10 F1 · security: On June 10, 2026, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:20 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $7.88 Strike: $7.88 | $157,600.00 |
DisclosureSEC source: 0001415889-25-015588 · form4-06042025_040607.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,545 Underlying: Common shares · 20,000 shares Expires 2035-06-03 F1 · security: On June 3, 2025, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 23:00 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $5.58 Strike: $5.58 | $111,600.00 |
DisclosureSEC source: 0001415889-24-021639 · form4-08192024_110850.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,545 Underlying: Common shares · 20,000 shares Expires 2034-08-15 F1 · security: On August 15, 2024, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 14:45 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001415889-23-009694 · form4-06132023_020622.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,545 Underlying: Common shares · 20,000 shares Expires 2033-06-12 F1 · security: On June 12, 2023, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the issuer's common shares pursuant to the issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 13:21 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001104659-22-071685 · tm2218610-1_4seq1.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2032-06-14 F1 · security: On June 14, 2022, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| June 29, 2021 Filed Jun 30, 2021 19:41 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.52 | $0.00 |
DisclosureSEC source: 0001104659-21-087512 · tm2121155-1_4seq1.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2031-06-29 F1 · security: On June 29, 2021, Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 19:14 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001104659-20-095442 · tm2027709d1_4.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2030-08-13 F1 · security: On August 13, 2020 Marco Brughera was granted a non-qualified stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Equity Incentive Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| June 18, 2019 Filed Jun 20, 2019 00:33 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001144204-19-031563 · tv523892_4.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2029-06-18 F1 · security: On June 18, 2019, Marco Brughera was granted an incentive stock option to purchase 20,000 shares of the Issuer's common shares pursuant to the Issuer's Amended and Restated Stock Option Plan. F2 · derivative.exercise_date: The option is 100% vested on the date of grant. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 14:41 UTC | FENNEC PHARMACEUTICALS INC. FENC · Entity 5601 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.93 | $0.00 |
DisclosureSEC source: 0001144204-18-033677 · tv496270_4.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2025-06-08 F1 · security: On June 8, 2018, Marco M. Brughera was granted an incentive stock option to purchase 20,000 common shares of the Issuer pursuant to the Issuer's Amended and Restated Stock Option Plan. The option is 100% vested on the date of grant. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 21:21 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | GrantStock Option (Right to Buy) · Derivative | 13,100 | $0.00 Strike: $2.29 | $0.00 |
DisclosureSEC source: 0001213900-17-006382 · f4060817brughera_soligenix.xml · derivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,100 Underlying: Common Stock · 13,100 shares Expires 2027-06-07 F1 · security: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. F1 · derivative.exercise_date: The stock option vests ratably on each of September 8, 2017, December 8, 2017, March 8, 2018 and June 8, 2018. Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 15:00 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock Warrant · Derivative | 2,500 | $0.00 Strike: $3.95 | $0.25 |
DisclosureSEC source: 0001213900-16-019532 · f4121616brughera_soligenix.xml · derivative · entry 2 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2021-12-15 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 15:00 UTC | SOLIGENIX, INC. SNGX · Entity 8067 | PurchaseCommon Stock | 2,000 | $3.16 | $6,319.80 |
DisclosureSEC source: 0001213900-16-019532 · f4121616brughera_soligenix.xml · nonDerivative · entry 1 Brughera Marco Maria · CIK 0001589776 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.